Search research articles
Contact Us
Filters
Showing results (1101-1110 of 1,482) with videos related to
Page
of 149
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Blood
|
January 15, 2020
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C D DiNardo, I S Tiong, A Quaglieri, et al.
JAMA Oncology
|
June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial
Nitin Jain, Michael Keating, Philip Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Cancer
|
March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
Elias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Open Forum Infectious Diseases
|
January 28, 2025
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Santiago Carrero Longlax, Kent J Koster, Ashish M Kamat, et al.
Communications Biology
|
May 20, 2026
Circulating metabolites associated with protection against Mycobacterium tuberculosis infection and inhibition of mycobacterial growth
Todia P Setiabudiawan, Lika Apriani, Julian Avila-Pacheco, et al.
Blood Advances
|
November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Cancer Discovery
|
April 27, 2023
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
The European Respiratory Journal
|
February 12, 2021
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model
Jan Heyckendorf, Sebastian Marwitz, Maja Reimann, et al.
Page
of 149
Search research articles
Search
Showing results (1101-1110 of 1,482) with videos related to
Sort By:
Page
of 149
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Blood
|
January 15, 2020
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C D DiNardo, I S Tiong, A Quaglieri, et al.
JAMA Oncology
|
June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial
Nitin Jain, Michael Keating, Philip Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Cancer
|
March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
Elias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Open Forum Infectious Diseases
|
January 28, 2025
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Santiago Carrero Longlax, Kent J Koster, Ashish M Kamat, et al.
Communications Biology
|
May 20, 2026
Circulating metabolites associated with protection against Mycobacterium tuberculosis infection and inhibition of mycobacterial growth
Todia P Setiabudiawan, Lika Apriani, Julian Avila-Pacheco, et al.
Blood Advances
|
November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Cancer Discovery
|
April 27, 2023
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
The European Respiratory Journal
|
February 12, 2021
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model
Jan Heyckendorf, Sebastian Marwitz, Maja Reimann, et al.
Page
of 149